Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Banking On S670 Stent, Pipeline For Vascular Business Rebound

This article was originally published in The Gray Sheet

Executive Summary

U.S. feasibility trials of Medtronic's INX neurovascular stent for the treatment of atherosclerotic vessels in the brain began Aug. 11, the company announced Aug. 23.

You may also be interested in...



Medtronic Entering $450 Mil. ENT Market Via $800 Mil. Xomed Acquisition

Acquisition of surgical ear nose and throat device maker Xomed Surgical Products under an Aug. 27 merger agreement valued at $800 mil. will mark Medtronic's entrance into the $450 mil. worldwide ENT market.

Medtronic Entering $450 Mil. ENT Market Via $800 Mil. Xomed Acquisition

Acquisition of surgical ear nose and throat device maker Xomed Surgical Products under an Aug. 27 merger agreement valued at $800 mil. will mark Medtronic's entrance into the $450 mil. worldwide ENT market.

Medtronic v. Tyco

California federal district court grants preliminary injunction against spinal fusion cage rival Surgical Dynamics (a division of Tyco's U.S. Surgical business) prohibiting it from selling its Ray TFC spinal implant fusion cage. Medtronic alleges that the device infringes patents for its Inter Fix threaded spinal fusion device. The injunction, which was announced Aug. 16 and reinforces an April 16 federal appeals court reversal in Medtronic's favor (1"The Gray Sheet" May 3, p. 19), is temporary pending completion of patent validity trial proceedings

Related Content

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel